Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Liver scan may predict deadly failure after big operations

NCT ID NCT02753517

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special liver scan (hepatobiliary scintigraphy) can predict liver failure in 326 patients undergoing major liver surgery. The scan measures how well the remaining liver works, which may be more useful than just measuring its size. If accurate, it could help doctors identify high-risk patients and improve surgical planning.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Hepatobiliary scintigraphy (imaging scan)
What this could lead to
If successful, this scan could help surgeons better predict which patients are at risk of liver failure after major liver surgery, potentially reducing complications.
What could go wrong
This is an observational study, not a treatment trial. The scan's accuracy may be limited, and results may not apply to all patients or hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

326 people

The number who actually took part.

Started

Dec 2015

Finished

Dec 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Noncirrhotic liver * Benign or malignant liver tumor * Anatomic hepatic resection ≥ 4 segments * Aged ≥18 * ASA Score ≤3 * Signed informed consent * Presence of contraception in non-menopausal women Exclusion Criteria: * Cirrhosis * Absence of preoperative biliary drainage in case of preoperative jaundice * Patient refusal * Absence of affiliation to Social Security * Body weight above 230kg * Known allergy to Hida derivatives

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatic insufficiency are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hepatic Insufficiency liver and intrahepatic bile duct neoplasm liver failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatic insufficiency

Contacts and locations

Locations

  • AP-HPHôpital Beaujon,

    Paris, France

  • CHRU, Hôpital Claude Huriez

    Lille, France

  • CHU

    Bordeaux, France

  • CHU

    Grenoble, France

  • CHU

    Marseille, France

  • CHU

    Rouen, France

  • CHU

    Toulouse, France

  • Centre Leon Berard - Lyon 08

    Lyon, 69008, France

  • Chru Nancy - Hopitaux de Brabois

    Nancy, France

  • Hopital Croix-Rousse - Hcl - Lyon 04

    Lyon, 69008, France

  • Hopital Estaing - Chu63 - Clermont Ferrand

    Clermont-Ferrand, France

  • Hôpital Nord, CHU

    Amiens, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.